RxDoctor Payments DataLook up a doctor →

Issam Makhoul, MD

Hematology & Oncology · Little Rock, ARNPI 1477643955

Payments from drug & device makers

$3,433,719in general payments, 2019–2025

Across 197 payments — averaging $17,430 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.4M
  • Merck$1.3M
  • AstraZeneca$286K
  • E.r. Squibb & Sons, L.L.C.$165K
  • Seagen Inc.$137K
  • Novartis$57K
  • plus $28K from 9 others

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,433,719 in reported general payments places this provider in the 95th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$3,266,344
Medicare patients
678
Services billed
135,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →